Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Acting Antiretroviral Therapy in Non-Adherent HIV-Infected Individuals
NCT03635788Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2019
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3 trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2019; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03635788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635788.